Navigation Links
National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
Date:5/17/2011

KING OF PRUSSIA, Pa., May 17, 2011 /PRNewswire/ -- CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX: CSL), is a recipient of the National Organization for Rare Disorders (NORD) 2011 Corporate Award. The award was presented this evening at the NORD Partners in Progress Celebration 2011 for "new treatments brought to market for patients with rare diseases."

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO)

CSL Behring's new treatment, factor XIII concentrate (human), is approved for the routine prophylactic treatment of congenital factor XIII deficiency, an extremely rare and potentially life-threatening bleeding disorder. Factor XIII concentrate (human) is the first and only dual sub-unit FXIII concentrate. It contains both A and B sub-units to treat FXIII patients regardless of sub-unit deficiency. Congenital factor XIII deficiency is estimated to affect one person in two million, with an incidence in the U.S. of approximately 150 people. (1)

"CSL Behring is honored to receive this NORD Corporate Award," said Paul Perreault, CSL Behring Executive Vice President for Worldwide Commercial Operations and incoming president. "People with rare diseases often face a host of challenges in being accurately diagnosed and in gaining ongoing access to appropriate medical care. CSL Behring focuses on these areas and partners with groups such as NORD to improve patients' lives. We commend NORD for their outstanding achievements and dedication to supporting people with rare diseases."

This award is the most recent in a series of recognitions for CSL Behring's innovative therapies used to treat rare and serious diseases. NORD previously honored CSL Behring for developing fibrinogen concentrate (human) for treating acute b
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
2. SyntheZyme Wins Second National Science Foundation Grant to Commercialize Promising Biopesticide
3. Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
4. International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment
5. MedImmune To Present Eight Abstracts on Projects Regarding Thoracic and Respiratory Issues at the Annual American Thoracic Society International Conference
6. Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results
7. Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula
8. Chindex International, Inc. Reports First Quarter 2011 Financial Results
9. Boston Scientific Begins U.S. and International Launch of Expect™ Endoscopic Ultrasound Aspiration Needle
10. Ferring Pharmaceuticals to Support Great Prostate Cancer Challenge® Events Across the Country in National Effort to End Prostate Cancer
11. Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... WOODCLIFF LAKE, N.J. and SAN ... announced today that its parent company Eisai Co., Ltd. ... Haruo Naito , "Eisai") and Halozyme Therapeutics, Inc. ... and CEO: Dr. Helen Torley , "NASDAQ: HALO") ... eribulin mesylate (brand name: Halaven ® , "eribulin") in ...
(Date:7/31/2015)... July 31, 2015  Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... Yujiro S. Hata to its board of directors. ... and corporate development is a tremendous asset to our ... chief executive officer of Xencor. "Xencor faces a range ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... N.J., Dec. 8, 2011  At the Radiological Society ... announced its plans to enter the radiology display ... in display technology to bring a comprehensive line ... "Sony has set the standard for ...
... Dec. 8, 2011 Ecology Coatings, Inc. ... development of nanotechnology-enabled, ultraviolet-curable advanced coatings, today announced ... the rigorous requirements of the healthcare industry.  The ... patient wristband and is benzophenone free—a request that ...
Cached Medicine Technology:Ecology Coatings Develops UV-Curable Coatings for Medical Wristbands 2Ecology Coatings Develops UV-Curable Coatings for Medical Wristbands 3
(Date:7/31/2015)... Orlando, FL (PRWEB) , ... July 31, 2015 , ... ... visiting the United States for temporary work, study or family visit for the past ... in their 80s and 90s are able to travel and spend time with their ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... apnea (OSA) and the growing number of individuals who remain undiagnosed, treatment options ... continue to shy away from traditional CPAP therapy due to its overall lack ...
(Date:7/30/2015)... ... ... The Venetian on Grace Bay in the Turks & Caicos Islands is pleased to announce ... 40% on their stay while enjoying some of the most beautiful ocean views in the ... a chance to reconnect with loved ones and rediscover one's best self. The sea ...
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across the country see the ... a serious challenge. Because of growing competition, it is more important than ever ... , The team at Wound Care Advantage has found that while ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The connection between a healthy head of hair ... The loss of a full head of hair can have a devastating impact on the ... is perceived in the work place, the consequences of hair loss are not to be ...
Breaking Medicine News(10 mins):Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:The Venetian on Grace Bay in Turks & Caicos Islands Offers 40% Savings This Fall. 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2
... Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- Two ... people with the rare bone marrow disorder called myelofibrosis. ... brand name Jakafi, won,t cure myelofibrosis, it can help ease ... to the studies. "This is probably the most ...
... report published this week in the New England Journal ... melanoma patients with a specific genetic mutation benefit from the ... to 15.9 months. In patients who responded, the drug stopped ... patients with a BRAF V600 mutation, this drug is a ...
... of Traumatic Brain Injury Research at Kessler Foundation, is an ... on March 6, 2012, in Washington, DC. Dr. Grafman ... brain injury. A well known expert, he will focus on ... injury and genetic polymorphisms on social abilities and quality of ...
... Colin Farrelly wants to see more research into remarkable ... live 100 years disease-free. He describes the current pathology-based ... biology" and suggest more resources should be focused on ... the question ,what causes disease?, is the most significant ...
... -- Strict enforcement of underage drinking laws reduces the ... new study suggests. State lawmakers have relied heavily on ... of alcohol under the legal age laws -- to control ... on young people aged 15 to 24 from the FBI,s ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) -- ... FDA mandate that would have forced tobacco companies to ... The proposed requirement from the U.S. Food and Drug ... would have emblazoned cigarette packaging with images of people ...
Cached Medicine News:Health News:New Drug May Help Fight Rare Bone Marrow Disorder 2Health News:New Drug May Help Fight Rare Bone Marrow Disorder 3Health News:Kessler Foundation neuroscientist addresses 2nd Annual TBI Conference in Washington DC 2Health News:Strict Underage Drinking Laws May Deter Delinquency in Teens 2Health News:Judge Blocks Plan for Graphic Cigarette Warnings 2
... basic laboratory system for pH and temperature ... obtained when used with a temperature probe ... and easy one and two-point calibration with ... (pH 1.68, 4.00, 7.00, 10.01 and 12.45) ...
... Detectors provide unmatched value and flexibility ... automation needs. Capable of performing fluorescence, ... same instrument, the DTX Series can ... be integrated seamlessly with Beckman Coulters ...
... Designed for High Throughput Screening ... of assays into HTS by sharing ... performance of Analyst AD, fluorescence intensity, ... Optimized for seamless integration into ...
... features for assay development and basic ... Reduces the inevitable transfer time required ... developed to meet the challenges of ... unparalleled detection performance for Fluorescence Intensity, ...
Medicine Products: